Semaglutide: Structure of a Lipidated GLP-1 Analogue

Semaglutide is a synthetic analogue of glucagon-like peptide-1 in which three targeted changes turn a hormone that survives only minutes in circulation into a molecule built for stability. As a semaglutide peptide profile, this article focuses on the chemistry: the backbone sequence, the substitution that blocks enzymatic cleavage, the lipid side chain that binds albumin, and what those features mean for synthesis, analysis and receptor assays.

For laboratories, semaglutide is useful as a well-characterised, selective agonist of the GLP-1 receptor and as a reference point when profiling multi-receptor agonists. It is available as the GLP-1 research peptide (semaglutide) for in vitro and preclinical work. If you are new to the parent hormone, start with our GLP-1 peptide overview.

Is semaglutide a peptide?

Yes. Semaglutide consists of 31 amino acid residues joined by amide (peptide) bonds, and its backbone follows the sequence of native GLP-1(7-37) with two residue substitutions. What sets it apart from a simple sequence variant is a non-peptide side chain, a fatty diacid attached through a short linker, which places it in the class of acylated or lipidated peptides. It also contains a non-proteinogenic amino acid, α-aminoisobutyric acid, so it cannot be produced as a finished molecule by ribosomal expression alone.

The molecular formula is C₁₈₇H₂₉₁N₄₅O₅₉, giving an average molecular weight of about 4113.6 g/mol, noticeably heavier than native GLP-1(7-37) at roughly 3.36 kDa. Most of the difference comes from the side chain.

The sequence and its three modifications

Using the conventional GLP-1 numbering, which starts at His7, semaglutide can be written as H-Aib-EGTFTSDVSSYLEGQAA-K(side chain)-EFIAWLVRGRG-OH. The C-terminus is the free acid of Gly37, matching GLP-1(7-37) rather than the amidated form.

Position	Native GLP-1	Semaglutide	Purpose
8	Ala	Aib	Blocks cleavage by dipeptidyl peptidase-4
26	Lys	Lys acylated via linker with C18 diacid	Reversible albumin binding
34	Lys	Arg	Leaves Lys26 as the single acylation site

Aib at position 8

Dipeptidyl peptidase-4 (DPP-4) inactivates native GLP-1 by removing the N-terminal His-Ala dipeptide. Replacing Ala8 with α-aminoisobutyric acid, which carries two methyl groups on its alpha carbon, makes the N-terminus a very poor substrate for the enzyme while keeping the residue small enough for the receptor to accept. Aib also restricts backbone conformation and is known to favour helical structure, a feature exploited in many peptide analogue programmes.

The Lys26 side chain

The epsilon-amino group of Lys26 carries a linear chain built from two units of 8-amino-3,6-dioxaoctanoic acid (a short oligo(ethylene glycol) spacer, often abbreviated OEG or ADO), then a γ-linked glutamic acid, and finally octadecanedioic acid, an 18-carbon fatty diacid attached through one of its carboxyl groups. The free terminal carboxylate of the diacid is a key design element: diacids bind serum albumin more strongly than the corresponding monoacids. The hydrophilic spacer distances the lipid from the peptide so that receptor recognition is less disturbed.

Arg at position 34

Native GLP-1 has two lysines. Substituting Lys34 with arginine conserves a positive charge at that position while removing a competing amine, so acylation chemistry can be directed to Lys26 without ambiguity.

From liraglutide to semaglutide

Semaglutide descends from liraglutide, an earlier analogue that already carried Arg34 and a Lys26 side chain, in that case a palmitoyl (C16 monoacid) group attached through γ-glutamic acid, while retaining native Ala8. The discovery work reported in 2015 explored series of fatty diacids and linkers, measuring receptor potency and albumin affinity side by side, and combined the stronger-binding C18 diacid and OEG spacer with the Aib8 substitution. The design accepted some loss of intrinsic receptor affinity in exchange for much tighter albumin association, a trade-off that is visible in assays run at different albumin concentrations.

Receptor pharmacology in vitro

Semaglutide is a selective agonist of the GLP-1 receptor (GLP-1R), a class B1 G protein-coupled receptor. Like the native hormone, it binds by a two-domain mechanism: the C-terminal helix engages the receptor’s extracellular domain, while the N-terminal region enters the transmembrane core and drives activation, principally through G_s coupling and cAMP production. It has no meaningful activity at the GIP or glucagon receptors, which distinguishes it from the dual and triple agonists covered in our tirzepatide vs semaglutide receptor pharmacology comparison. Those multi-receptor compounds and other incretin-class ligands are listed alongside it in the research peptides category.

Albumin is the main variable to control. Because only the unbound fraction can reach the receptor, the apparent potency of a lipidated analogue shifts to higher concentrations as albumin content in the assay buffer rises. Results from serum-free buffer, buffer with a low percentage of bovine serum albumin and buffer with higher albumin are not directly comparable, so the albumin source and concentration should always be reported. Species orthologues of the receptor and of albumin can also differ in their interactions with the peptide and the lipid.

Synthesis and analytical characterisation

Laboratory-scale material is typically prepared by Fmoc solid-phase peptide synthesis. Aib couplings are slow because of steric hindrance at the alpha carbon and usually need stronger activation or extended coupling times. The side chain can be built on resin after selective deprotection of an orthogonally protected Lys26, or attached in solution to a purified precursor peptide. Large-scale manufacture has also used semi-recombinant routes in which an expressed precursor is elaborated chemically.

For identity, mass spectrometry is the primary tool; electrospray spectra show a series of multiply charged ions that deconvolute to the expected mass, and the lipid makes the molecule markedly more hydrophobic than native GLP-1, so it elutes later in reversed-phase HPLC. Purity methods must resolve closely related impurities such as deletion sequences, incompletely acylated peptide and isomers formed at the glutamic acid linkage. Like native GLP-1, semaglutide tends to be least soluble in mildly acidic conditions near its isoelectric point and dissolves more readily at neutral to slightly basic pH. Our guides to peptide mass spectrometry explain how to read these results.

What researchers should take from the structure

Each modification in semaglutide answers a specific weakness of the native hormone: Aib8 resists DPP-4, the C18 diacid side chain binds albumin, and Arg34 makes the chemistry clean. In practice this means treating it as a distinct lipidated molecule rather than as interchangeable with GLP-1(7-37), controlling albumin in every receptor assay, and verifying mass and purity before use. When the GLP-1 peptide research material (semaglutide) serves as a reference agonist, record the lot number and check its certificate of analysis against your own identity data. This material is for laboratory research use only and is not for human or veterinary use.

References

1. Lau J, Bloch P, Schäffer L, et al. Journal of Medicinal Chemistry. 2015;58(18):7370–7380.
2. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology. 2019;10:155.
3. Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007;87(4):1409–1439.
4. Mentlein R, Gallwitz B, Schmidt WE. European Journal of Biochemistry. 1993;214(3):829–835.
5. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. Journal of the American Chemical Society. 1963;85(14):2149–2154.